Deciphera Pharmaceuticals, Inc. to Report Clinical Data with DCC-2618 at the Upcoming 2018 American Society for Clinical Oncology (ASCO) Annual Meeting

On April 25, 2018 Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, reported that an abstract highlighting DCC-2618, the Company’s KIT and PDGFRα inhibitor, has been selected for poster presentation and discussion at the 2018 American Society for Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place June 1-5, 2018 in Chicago, IL (Press release, Deciphera Pharmaceuticals, APR 25, 2018, View Source [SID1234525689]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the presentation on DCC-2618 are as follows:

Poster Title: Mutation profile of drug resistant gastrointestinal stromal tumor (GIST) patients (pts) enrolled in the phase 1 study of DCC-2618.

Author: Suzanne George, Dana-Farber Cancer Institute
Session: Sarcoma, Poster and Discussion Session
Abstract #: 11511
Poster Board #: 256
Date & Time: Saturday June 2, 20183:00 PM – 4:15 PM CT
Location: Hall A, S404, McCormick Place, Chicago, IL

About DCC-2618

DCC-2618 is a KIT and PDGFRα kinase switch control inhibitor in clinical development for the treatment of KIT and/or PDGFRα-driven cancers, including gastrointestinal stromal tumors, or GIST, systemic mastocytosis, or SM, and glioblastoma multiforme. DCC-2618 was specifically designed to improve the treatment of GIST patients by inhibiting a broad spectrum of mutations in KIT and PDGFRα. DCC-2618 is a KIT and PDGFRα inhibitor that blocks initiating and secondary KIT mutations in exons 9, 11, 13, 14, 17, and 18, involved in GIST as well as the primary D816V exon 17 mutation involved in SM. DCC-2618 also inhibits primary PDGFRα mutations in exons 12, 14,and 18, including the exon 18 D842V mutation, involved in a subset of GIST.